This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Compugen Ltd. (
NASDAQ: CGEN) today announced that it will present at the Immunology 2014 Conference to be held May 2-6 in Pittsburgh. Immunology 2014, the annual meeting of the American Association of Immunologists, is a premier international scientific meeting at which world leaders in immunology present their research. Compugen’s presentation will take place in a session entitled “Harnessing Cellular and Molecular Interactions in Autoimmunity” on Tuesday, May 6, 2014.
In her presentation, Iris Hecht, PhD, Principal Scientist at Compugen, will review results for CGEN-15001, an Fc fusion protein based on one of the immune checkpoint candidates discovered by the Company. These results for CGEN-15001, obtained in
in-vitro systems and multiple models of autoimmune diseases, demonstrate this product candidate’s efficacy and unique mode-of-action, including promotion of regulatory T cells and its potential for induction of long-term immune tolerance. Immune tolerance induction is a highly sought-after approach for treatment of autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis.
The results being presented by Dr. Hecht include data from Compugen’s long-standing collaboration with Stephen Miller, Judy Gugenheim Research
Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine. Compugen also announced today that the scope of this collaboration has been expanded to now include activities to further characterize the immune function of a number of Compugen-discovered checkpoint target candidates, in addition to further studies involving CGEN-15001. The CGEN-15001 studies will address its potential for ameliorating autoimmunity through the induction of immune tolerance, and will include translational research using biological samples from autoimmune patients.
Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “We are pleased to participate in this important conference to be attended by world leading researchers in the field of immunology. Our participation will take the form of both a poster and an oral presentation reviewing the promising results for CGEN-15001, our leading candidate for therapeutic use in immunology. Looking ahead, we expect that the extended long-term collaboration with Professor Miller and Northwestern University will further demonstrate the unique therapeutic potential of this candidate for treatment of multiple autoimmune diseases, as well as advance the research and validation of a number of other Compugen discovered immune checkpoint target candidates.”